WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting the transferrin receptor (TfR), which enables drugs to be transported across the blood brain barrier and into the central nervous system. TfR-specific Nanofitins, also known as brain shuttles, are designed to be combined with other treatment modalities including peptides, small molecules, and antibodies.
“This agreement extends Apellis’ ongoing research to develop brain-active C3 inhibitors with a highly efficient approach to deliver targeted complement therapies into the brain,” said Lukas Scheibler, Ph.D., chief innovation officer at Apellis. “Studies suggest that complement overactivation may play a role in several neurodegenerative diseases. By combining Affilogic’s brain shuttle technology with our deep expertise in complement, we aim to develop novel therapies that control complement in these devastating neurological diseases with high unmet need.”
The companies also continue to collaborate on the discovery of Nanofitin-based therapies that target C3, the central protein of the complement cascade. Several research programs are in development including two pre-clinical candidates for which Apellis expects to submit investigational new drug applications (INDs) over the next 12 months: APL-1030, a potential first-in-class, brain-active C3 inhibitor for neurodegenerative and other complement-driven diseases, and APL-2006, an ophthalmological candidate in development to treat both wet age-related macular degeneration (AMD) and geographic atrophy.
“We are excited to expand our partnership with Apellis, a leader in targeting the complement pathway, to include our proprietary TfR-specific Nanofitin, which enables delivery to the brain of a wide range of treatment modalities. The pre-clinical data generated so far on the Nanofitins illustrate nicely that we can seamlessly create binders that inhibit multiple targets,” said Olivier Kitten, Ph.D., chief executive officer of Affilogic. “Our ongoing R&D collaboration highlights Affilogic’s strategy of assembling Nanofitins to develop custom biomolecules for partners, and we look forward to the continued advancement of the research programs toward the clinic.”
Under the terms of the expanded agreement, Apellis secured exclusive, sublicensable, worldwide patent rights for all development projects. Affilogic currently receives research costs and will be eligible to receive development milestone payments and royalty payments on net sales of any product approved out of this collaboration.
About Nanofitins® For any biological target, from peptides to entire cells, it is possible to generate custom Nanofitins® with a high binding affinity and controlled specificity for targeting or interacting purposes. They can thereby be designed as targeted inhibitors, or as vectors for specific transport. Each Nanofitin is 20 times smaller than an antibody and hyperstable. Nanofitins are easily combined with each other or third-party molecules by simple, rapid and proven methods to design an ideal targeted molecule. Usual systemic routes can be travelled by Nanofitins aiming at neutralizing relevant interactions. Intrinsic properties of Nanofitins® make them amenable to other routes, such as oral route and pulmonary delivery.
About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
About Affilogic Affilogic is an independent private company established in Nantes, France, and specialised in the discovery, development and combinations of affinity proteins named Nanofitins® as biotherapeutics through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector. Affilogic has exclusive and worldwide rights to this technology from the Pasteur Institute and the CNRS, and a proprietary patent portfolio has been established and continues to grow. For more information, please visit https://affilogic.com
Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q with the Securities and Exchange Commission on May 4, 2022 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Apellis Media Contact: Lissa Pavluk media@apellis.com 617.977.6764
Investor Contact: Meredith Kaya meredith.kaya@apellis.com 617.599.8178
Affilogic Nadège Prel nadege@affilogic.com
Sanofi stock bounded higher Friday after its GSK-partnered Covid shot tamped down on omicron infections in a Phase 3 study.
Is Pfizer stock a buy after the FDA signed off on its Covid vaccine for babies and toddlers? Is PFE stock a buy right now?
Earlier this month, the S&P 500 officially entered a bear market; its current year-to-date loss stands at 21%, and the NASDAQ, which has fallen faster and farther, stands at a 30% ytd loss. The rapid reversal not only put the bulls back in the corral, but also erased all of last year’s stock market gains, leading most analysts to start meditating on the prospects of recession. Among the headwinds they’re considering are the highest rates of inflation in over 40 years and in response, a sharp tur
Is Moderna stock a buy after the FDA authorized its Covid vaccine for children as young as 6 months old? Is MRNA stock a buy right now?
Sanofi and GSK's joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines.
Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company updated the study's ClinicalTrials.gov
The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.
A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumour agnostic. The Food and Drug Administration early on Thursday granted accelerated approval for the combination of the two drugs Tafinlar and Mekinist for adults and children as young as six with inoperable or metastatic solid tumours with a mutation known as BRAF V600, who have exhausted other treatment options. Earlier this month, the oral drug combination showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.
Is Merck stock a sell after shares sacrificed their breakout amid recent market volatility? Is MRK stock a sell right now?
COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original strain, although some experts suggest they may only offer significant benefits for older and immunocompromised people. Moderna, Pfizer and Novavax have been testing vaccines based on the first BA.1 Omicron variant that became dominant last winter, driving a massive surge in infections. On Wednesday, Moderna said its updated vaccine worked well against more recent Omicron subvariants, and that it was moving forward with plans to ask regulators for approval.
The CDC recommended use of Moderna’s Covid-19 vaccine in children 6 to 17 years, the final step in allowing the shots to become widely available.
Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the beta variant and the original strain of the virus. Related: Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential A
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from the Phase 3 P
Advisers to the Centers for Disease Control and Prevention backed use of Moderna Inc.’s Covid-19 vaccine in children ages 6 to 17 years.
WASHINGTON (Reuters) -A pill used to terminate early pregnancies is unlikely to become available without a prescription for years, if ever, experts told Reuters, as the conservative-leaning U.S. Supreme Court dramatically curbed abortion rights this week. The Supreme Court on Friday overturned the landmark 1973 Roe v. Wade ruling that recognized the constitutional right to an abortion and legalized it nationwide. The pill, mifepristone, in combination with a second drug called misoprostol, induces an abortion up to 10 weeks into a pregnancy and is only available through a certified doctor's prescription.
The European Medicines Agency said Thursday it is recommending the authorization of the coronavirus vaccine made by French pharmaceutical Valneva, making it the sixth shot given the green light in Europe. The EU drug regulator said in a statement that it had cleared Valneva's two-dose vaccine for people aged 18 to 50. The main study used to assess Valneva's vaccine was research in about 3,000 people aged 30 and over; scientists compared it to the AstraZeneca COVID-19 vaccine.
The major stock market indexes are all up and are trading slightly lower than the highs of the morning, with all three major indexes relatively flat over the last hour. The Nasdaq composite is up 2.3% while the S&P 500 is up 2.
Hong Kong's second special-purpose acquisition company (SPAC), Vision Deal, is reviewing a shortlist of potential merger targets, as Chinese entrepreneurs and companies including Geely-backed carmaker Polestar test-drive the investment vehicle as an alternative route to a public listing. Vision Deal is looking at a number of candidates at the moment, including the largest or second-largest leaders in smart-car technologies, supply chain, and cross-border e-commerce, said Wei Zhe, chairman and ex
The tech investment arm of the South Korean conglomerate reportedly halted the plan to issue its own cryptocurrency, citing the macroeconomic environment and trust issues related to cryptocurrencies. See related article: South Korea’s second-largest conglomerate to issue own cryptocurrency Fast facts SK Square told local news agency Newsis that preparations for trademark applications and the […]
Following the PMI reports, Euro Zone money markets were pricing in about 30 basis points (bps) of rate hikes in July compared to 34 bps on Monday.